Skip to main content
Top
Published in: Neurological Sciences 2/2015

01-02-2015 | Original Article

Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs

Authors: Michela Ponzio, Simone Gerzeli, Giampaolo Brichetto, Daiana Bezzini, Gian Luigi Mancardi, Paola Zaratin, Mario Alberto Battaglia

Published in: Neurological Sciences | Issue 2/2015

Login to get access

Abstract

The study estimates the cost of multiple sclerosis (MS) in Italy quantifying the impact of the rehabilitation on cost of illness. Patients with MS were enrolled at MS clinical centres, in rehabilitation units and among members with MS of the Italian MS Society across the Italy. The MS costs were captured with a questionnaire and were estimated taking into account both healthcare and non-healthcare costs as well as the productivity losses. Mean total annual costs per patients were €37,948, increasing for different disease severity: from €22,750 at an EDSS score of 0–3 to €63,047 at an EDSS score equal to or more than 7. €3,418 was due to rehabilitation (about 26.7 % of direct healthcare costs) and of these 44 % was attributable to admission to rehabilitation. The multivariate analysis showed a consistent trend toward increased total cost with progressive severity of MS, with presence of relapses, while the total cost decreases with a better quality of life. The burden increases as the MS becomes more severe and with relapse occurrence, moreover we observed high costs due to admission to rehabilitation suggesting that different rehabilitation setting might be considered to reduce the financial burden and increase the quality of life for person with MS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pugliatti M, RosatiG Carton H, Riise T, Drulovic J, Vecsei L, Milanov I (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13:700–722CrossRefPubMed Pugliatti M, RosatiG Carton H, Riise T, Drulovic J, Vecsei L, Milanov I (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13:700–722CrossRefPubMed
3.
go back to reference Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19:155–162CrossRefPubMed Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19:155–162CrossRefPubMed
4.
go back to reference Naci H, Fleurence R, Birt J, Duhig A (2010) Economic burden of multiple sclerosis. A systematic review of the literature. Pharmacoeconomics 28(5):363–379CrossRefPubMed Naci H, Fleurence R, Birt J, Duhig A (2010) Economic burden of multiple sclerosis. A systematic review of the literature. Pharmacoeconomics 28(5):363–379CrossRefPubMed
5.
go back to reference Amato MP, Battaglia MA, Caputo D, Fattore G, Gerzeli S, Pitaro M, Reggio A, Trojano M, for the Mu. S. I. C. Study Group (2002) The costs of multiple sclerosis: a cross-sectional, multi center cost-of-illness study in Italy. J Neurol 249:152–163CrossRefPubMed Amato MP, Battaglia MA, Caputo D, Fattore G, Gerzeli S, Pitaro M, Reggio A, Trojano M, for the Mu. S. I. C. Study Group (2002) The costs of multiple sclerosis: a cross-sectional, multi center cost-of-illness study in Italy. J Neurol 249:152–163CrossRefPubMed
6.
go back to reference Karampampa K, Gustavsson A, Miltenburger C, Teruzzi C, Fattore G (2012) Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler J 18(Suppl 2):29–34CrossRef Karampampa K, Gustavsson A, Miltenburger C, Teruzzi C, Fattore G (2012) Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler J 18(Suppl 2):29–34CrossRef
7.
go back to reference Kobelt G, Berg J, Lindgren P, Battaglia MA, Lucioni C, Uccelli A (2006) Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 7:S45–S54CrossRefPubMed Kobelt G, Berg J, Lindgren P, Battaglia MA, Lucioni C, Uccelli A (2006) Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 7:S45–S54CrossRefPubMed
9.
go back to reference Beer S, Khan F, Kesselring J (2012) Rehabilitation interventions in multiple sclerosis: an overview. J Neurol 259:1994–2008CrossRefPubMed Beer S, Khan F, Kesselring J (2012) Rehabilitation interventions in multiple sclerosis: an overview. J Neurol 259:1994–2008CrossRefPubMed
10.
go back to reference Kobelt G, Berg J, Lindgren P, Jönsson B (2006) Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 7(Suppl 2):S5–S13CrossRefPubMed Kobelt G, Berg J, Lindgren P, Jönsson B (2006) Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 7(Suppl 2):S5–S13CrossRefPubMed
11.
go back to reference The EuroQoL Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef The EuroQoL Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef
12.
13.
go back to reference Posnett J, Jan S (1996) Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 5:13–23CrossRefPubMed Posnett J, Jan S (1996) Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 5:13–23CrossRefPubMed
14.
go back to reference Koopmanschap MA, Rutten FF (1993) Indirect costs in economic studies. Pharmacoeconomics 4:446–454CrossRefPubMed Koopmanschap MA, Rutten FF (1993) Indirect costs in economic studies. Pharmacoeconomics 4:446–454CrossRefPubMed
15.
go back to reference Kind P, Hardman G and Macran S (1999) UK population norms for EQ-5D. York Centre for Health Economics, Discussion Paper, University of York Kind P, Hardman G and Macran S (1999) UK population norms for EQ-5D. York Centre for Health Economics, Discussion Paper, University of York
16.
go back to reference McCrone P, Heslin M, Knapp M, Bull P, Thompson A (2009) Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 26(10):847–860 (Erratum in: Pharmacoeconomics 27(4):354)CrossRef McCrone P, Heslin M, Knapp M, Bull P, Thompson A (2009) Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 26(10):847–860 (Erratum in: Pharmacoeconomics 27(4):354)CrossRef
17.
go back to reference Patwardahn MB, Mathcar DB, Samsa GP, McCrory DC, Williams DG, Li TT (2005) Cost of multiple sclerosis by level of disability; a review of literature. Mult Scler 11:232–239CrossRef Patwardahn MB, Mathcar DB, Samsa GP, McCrory DC, Williams DG, Li TT (2005) Cost of multiple sclerosis by level of disability; a review of literature. Mult Scler 11:232–239CrossRef
Metadata
Title
Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs
Authors
Michela Ponzio
Simone Gerzeli
Giampaolo Brichetto
Daiana Bezzini
Gian Luigi Mancardi
Paola Zaratin
Mario Alberto Battaglia
Publication date
01-02-2015
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 2/2015
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-014-1925-z

Other articles of this Issue 2/2015

Neurological Sciences 2/2015 Go to the issue